Hospital.Help

Cologne – People with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping mutations (METex14) may benefit from targeted therapy with capmatinib, according to the final results of the global phase 2 study GEOMETRY mono-1 show (Lancet Oncology, DOI: 10.1016/S1470-2045(24)00441-8). Accordingly, capmatinib is effective and tolerated both in the first line and in later lines. At about 3 to…